Biosimulation and intelligence solutions provider Simulations Plus has unveiled a new version of its ML platform, ADMET Predictor: Version 12.0. The platform aims to facilitate the discovery, design, and optimization of new molecules useful to the biopharma industry.

The latest version of the platform includes new features such as enhanced predictive models, high-throughput pharmacokinetics (HTPK), AI-driven drug design, a new drug-induced liver injury (DILI) module, boosted ANN Regression Models, and general usability improvements. The company asserts that the updated version comes with advanced data, algorithms, and descriptors, enhancing predictive capabilities that will offer improved accuracy and flexibility, particularly in high-throughput studies, AI-driven drug design, and early drug development involving DILI predictions.

Simulations Plus provides modeling and simulation software and pharmaceutical safety and efficacy services. The company offers a range of biosimulation solutions integrating AI/ML, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Its software products and services are designed to aid drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization.